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The putative modular polyketide synthase (PKS) that
prescribes biosynthesis of the bryostatin natural
products from the uncultured bacterial symbiont of
the marine bryozoan Bugula neritina possesses a
discrete open reading frame (ORF) (bryP) that en-
codes a protein containing tandem acyltransferase
(AT) domains upstream of the PKS ORFs. BryP is
hypothesized to catalyze in trans acylation of the
PKSmodules for polyketide chain elongation. To ver-
ify conservation of function,bryPwas introduced into
AT-deletion mutant strains of a heterologous host
containing a PKS cluster with similar architecture,
andpolyketideproductionwaspartially rescued.Bio-
chemical characterization demonstrated that BryP
catalyzes selective malonyl-CoA acylation of native
and heterologous acyl carrier proteins and complete
PKSmodules in vitro. The results support the hypoth-
esis that BryP loads malonyl-CoA onto Bry PKS
modules, and provide the first biochemical evidence
of the functionality of the bry cluster.
INTRODUCTION
Evidence is mounting that many bioactive natural products
isolated from marine invertebrates (e.g., sponges, ascidians,
bryozoans) are produced by microbial symbionts (reviewed by
Konig et al. [2006], Piel [2004], and Salomon et al. [2004]). Partic-
ularly compelling evidence indicates that the bryostatins, ecolog-
ically relevant bioactive compounds isolated from the temperate
marine bryozoan, Bugula neritina, are produced by the uncul-
tured microbial symbiont ‘‘Candidatus Endobugula sertula’’ that
resides in B. neritina (Davidson et al., 2001; Lopanik et al.,
2004b; Lopanik et al., 2006b). To date, different populations of
B. neritina-‘‘Ca. Endobugula sertula’’ have yielded 20 different
bryostatins (Lopanik et al., 2004a; Pettit, 1996). Each of these
molecules bears an identical polyketide core, but is distinguishedChemistry & Biology 15, 1175–11by its pendant acyl groups at two positions in the bryolactone ring
system. The pharmacological activity of bryostatin 1 has been
extensively studied; it has been shown to activate protein kinase
C (reviewed by Mutter and Wills [2000]) and exhibits anticancer
activity, as well as promise against neurodegenerative disorders,
including Alzheimer’s disease (Etcheberrigaray et al., 2004; Sun
and Alkon, 2005). To date, the National Cancer Institute lists 38
completed, ongoing, or planned clinical trials using bryostatin 1
as a single or combination therapeutic, and its importance as
a molecular probe to understand specific neurological disorders
is also increasing.
Recently, the 77 kb biosynthetic gene cluster (bry) that is puta-
tively responsible for assembly and tailoring of the bryostatins
was cloned and sequenced from two geographically distinct
sibling species of ‘‘Ca. Endobugula sertula’’/B. neritina (Fig-
ure 1A) (Davidson and Haygood, 1999; Hildebrand et al., 2004;
Sudek et al., 2007). The bry genes from the deep-water California
(CA) sibling species are positioned on at least two loci of the
chromosome, while the gene cluster from the shallow-water
North Carolina (NC) sibling species appears to reside on a contig-
uous fragment of DNA. All evidence suggests that bry encodes
the enzymes necessary for bryostatin biosynthesis, but, as
‘‘Ca. Endobugula sertula’’ has been refractory to cultivation
efforts, gene disruption and complementation have not been
possible. Portions of bry have been shown by PCR to be absent
in antibiotic-cured B. neritina (Davidson et al., 2001; Lopanik
et al., 2006a), and colocalization of 16S rRNA of ‘‘Ca. Endobu-
gula sertula’’ and a fragment of the PKS genes using in situ hy-
bridizations on B. neritina larvae (Davidson et al., 2001) provide
evidence for their bacterial origin. Moreover, analysis of PKS
fragments amplified from B. neritina-derived ‘‘Ca. Endobugula
sertula’’ metagenome samples revealed that bry is the only bio-
synthetic locus large enough to specify assembly of bryostatin
metabolites (Davidson et al., 2001).
Bacterial type I PKSs are large multifunctional enzymes that
produce complex polyketide molecules in an assembly line man-
ner (reviewed by Fischbach and Walsh [2006]). The group of en-
zymatic domains responsible for one chain elongation step is
termed a module. Three enzymatic domains comprise a minimal
module in PKS biosynthesis: the acyltransferase (AT), the acyl86, November 24, 2008 ª2008 Elsevier Ltd All rights reserved 1175
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Trans-Acylation in Bryostatin BiosynthesisFigure 1. Organization and Orientation of Biosynthetic Gene Clusters and Discrete AT Didomains
(A) Presumed bryostatin gene cluster from shallow-water ‘‘Candidatus Endobugula sertula’’-B. neritina populations (Sudek et al., 2007). Enzymatic domains
overexpressed in this study are zoomed. Modules putatively responsible for the portions of the bryostatin precursor, ‘‘bryostatin 0,’’ are noted.
(B) Mupirocin (PA) gene cluster from P. fluorescens NCIMB 10586 (El-Sayed et al., 2003).
Scale bar, 1 kbp for (A) and (B).carrier protein (ACP), and the ketosynthase (KS). The AT cata-
lyzes covalent linkage of the CoA-activated extender unit onto
the ACP, and the KS domain catalyzes condensation of each
extender unit, resulting in elongation of the polyketide chain by
two carbons. Often, there are additional domains within a mod-
ule, termed b-keto processing domains, which act to modify the
b-carbonyl, the ketoreductase (KR), the dehydratase (DH), and
the enoyl reductase. After full extension and reduction of the
polyketide chain, it is released in either a cyclized or linear form,
typically catalyzed by a thioesterase domain operating at the end
of the pathway. Following release from the PKS, the natural
product can be further modified by tailoring enzymes, such
as oxygenases, methyltransferases (MTs), and glycosyltrans-
ferases (reviewed by Rix et al. [2002]).
One significant feature of the putative bryostatin PKS is the
absence of AT domains within the polypeptides. Instead, a single
ORF (bryP) encoding two AT domains is present directly
upstream of the PKS genes in the NC-derived gene cluster (Fig-
ure 1A) (Sudek et al., 2007). There are several other PKS and
hybrid PKS/nonribosomal peptide synthetase (NRPS) clusters
that have discrete AT domains (termed ‘‘trans-AT’’), including lei-
namycin (Cheng et al., 2003), lankacidin (Mochizuki et al., 2003),1176 Chemistry & Biology 15, 1175–1186, November 24, 2008 ª200mupirocin (Figure 1B) (El-Sayed et al., 2003), pederin (Piel, 2002),
onnamide (Piel et al., 2004), rhizoxin (Partida-Martinez and Hert-
weck, 2007), mycosubtilin (Duitman et al., 1999), myxovirescin
(Simunovic et al., 2006), virginamycin M (Pulsawat et al., 2007),
difficidin (Chen et al., 2006), macrolactin (Chen et al., 2006;
Schneider et al., 2007), and bacillaene (Butcher et al., 2007;
Moldenhauer et al., 2007). In these AT-less modules, there are
well-defined remnants of AT domains that are hypothesized to
aid in docking of the trans-AT protein, although this has yet to
be confirmed experimentally (Nguyen et al., 2008; Tang et al.,
2004). The first in vitro experiment demonstrating that a trans-
AT is able to load malonyl-CoA onto excised ACPs was per-
formed with the discrete AT (LmnG) and ACPs from the leinamy-
cin gene cluster (Cheng et al., 2003). Furthermore, LmnG was
shown to load malonyl-CoA onto a tridomain portion of LmnJ
(DH-ACP-KR). Subsequent studies have shown that discrete
ATs are able to load malonyl-CoA onto cognate discrete and
excised ACPs (Calderone et al., 2006, 2007). It is proposed by
Nguyen et al. (2008) that discrete AT domains act in trans, load-
ing the extender unit onto the ACP of the AT-less module, but this
has yet to be demonstrated in vitro with a complete native PKS
module.8 Elsevier Ltd All rights reserved
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Trans-Acylation in Bryostatin BiosynthesisIn addition to bry, several other PKS and PKS/NRPS gene
clusters encode multiple discrete AT domains. The pederin sys-
tem from the microbial symbiont of the beetle Paederus fucipes
has two AT domains on two different ORFs (Piel, 2002), while
the bacillaene gene cluster from two Bacillus species has three
AT domains on three different ORFs (Butcher et al., 2007; Chen
et al., 2006; Moldenhauer et al., 2007). The bryostatin gene
cluster has two AT domains encoded on a single ORF (BryP),
and several other gene clusters also have trans-AT didomain
ORFs, including the mupirocin gene cluster from Pseudomonas
fluorescens (mmpC) (El-Sayed et al., 2003), the myxovirescin
gene cluster from Myxococcus xanthus (taV) (Simunovic et al.,
2006), and the rhizoxin gene cluster from Burkholderia rhizoxina
(rhiG) (Partida-Martinez and Hertweck, 2007). Gene disruption
studies of the complete didomain were performed for both taV
(Simunovic et al., 2006) and rhiG (Partida-Martinez and Hert-
weck, 2007), and, in both cases, secondary metabolite produc-
tion was completely abolished. Similarly, when the second AT
domain of MmpC (AT2) was deleted from the genome of
P. fluorescens, no mupirocin was detected in the supernatant
of the mutant strain (El-Sayed et al., 2003). Upon complementa-
tion with a plasmid bearing mmpC, mupirocin production was
restored to wild-type levels, demonstrating the necessity of
MmpC AT2 for mupirocin biosynthesis. Although it is clear that
the trans-AT domains are required for biosynthesis, the purpose
of two AT domains on a single ORF remains enigmatic.
In this article, we explore the substrate specificity of BryP in vivo
and in vitro. Mono- and didomain constructs of BryP were intro-
duced into P. fluorescens mmpC AT1 and AT2 deletion mutants,
and restoration of mupirocin production for one AT resulted. We
investigated the substrate specificity in vitro by assessing the
ability of the bryP-encoded AT mono- and didomains to transfer
malonyl- or methylmalonyl-CoA to a variety of carrier proteins
from the bryostatin PKS and other heterologous PKS and NRPS
systems. We demonstrate that BryP is able to transfer malonyl-
CoA onto the ACP domain of a full native module from the bryos-
tatin PKS. Furthermore, to our knowledge, this work represents
thefirstexample of biochemical studies onenzymes froma micro-
bial symbiont-derived natural product biosynthetic pathway.
RESULTS AND DISCUSSION
Sequence and Phylogenetic Analysis
of BryP AT1 and AT2
The DNA sequences of the shallow-water NC and deep-water
CA AT didomain bryP are 98.5% identical, and the correspond-
ing amino acid sequences are 96.8% identical (98.4% similar).
BryP AT1 and AT2 from shallow-water NC populations share
only 25.9% identity with each other at the amino acid level, but
both domains contain the necessary signature sequences
found in functional ATs from fatty acid and polyketide synthases
(see Figure S1 available online). Notably, the N-terminal (P/S/T)
GQGSQ loop that makes up one side of the active site binding
cleft is present in both BryP AT1 (residues 8–13) and BryP AT2
(322–327). Additionally, the catalytic dyad (Ser-His) is present
in both domains. Considerable investigation during the past
few years (Petkovic et al., 2008; Reeves et al., 2001) has enabled
prediction of the substrate preference for each AT domain, and
an ability to correlate selectivity to key amino acid motifs. BasedChemistry & Biology 15, 1175–11on multiple sequence alignments, BryP AT1 shares all character-
istics of a malonyl-CoA-specific AT (Figure S1). BLAST analysis
revealed that BryP AT1 is most similar to the PksC AT domain
from the bacillaene gene cluster inBacillus subtilis subsp. subtilis
str. 168 (NP_389591; e value = 8 3 1077; 55% identity), and to
BaeC from Bacillus amyloliquefaciens FZB42 (YP_001421285;
e value = 2 3 1076; 54% identity). BryP AT2 is most similar to
an AT domain identified in the genome sequence of Clostridium
cellulolyticum H10 (ZP_01574356.1; e value = 8 3 1056; 38%
identity), to BaeD, a discrete AT from the bacillaene cluster of
B. amyloliquefaciens FZB42 (CAG23951.1; e value = 4 3 1045;
33% identity [Chen et al., 2006]), and to PedC, a discrete
AT encoded in the pederin gene cluster (AAS47559.1; e value =
4 3 1040; 34% identity [Piel, 2002]). However, due to lack of
a structural model for BryP AT2 and its closest homologs, the
role that specific residues lining the active site pocket play in
substrate specificity is more difficult to predict.
Phylogenetic analysis of the amino acid sequences suggests
that BryP AT1 is closely related to AT domains from bacterial
FASs (Figure 2). These discrete enzymes utilize malonyl-CoA as
a substrate for fatty acid biosynthesis (Hopwood and Sherman,
1990). Other PKS trans-AT domains (MmpC AT2, PedD, RhiG
AT2, LmnG, DifA) form a clade together with BryP AT1. Interest-
ingly, BryP AT2 diverges from these FAS-related AT domains,
and forms a clade with another group of trans-AT domains, in-
cluding MmpC AT1 (El-Sayed et al., 2003), RhiG AT1 (Partida-
Martinez and Hertweck, 2007), PedC (Piel, 2002), and BaeD
(Chen et al., 2006), which appears to be more closely related to
embedded PKS AT domains (Figure 2). While all trans-AT PKSs
that have been sequenced to date have a discrete AT domain
from the former category (e.g., related to FAS AT), only a few
have a discrete AT from the latter category (i.e., PKS-embedded
AT). Of those with two or three AT domains (e.g., bryostatin
[Sudek et al., 2007], mupirocin [El-Sayed et al., 2003], bacillaene
[Cheng et al., 2003], myxovirescin A1 [Simunovic et al., 2006],
rhizoxin [Partida-Martinez and Hertweck, 2007], and pederin
[Piel, 2002]), two AT domains are encompassed on a single ORF
for most of these clusters. However, it is unclear why some PKS
gene clusters contain more than one trans-AT domain. As ‘‘Ca.
Endobugula sertula’’ remains refractory to laboratory culture, it
is not possible to assess function of the two AT domains compris-
ing bryP by traditional gene disruption and complementation
assays. Instead, a related surrogate system was employed to
test functional rescue of AT activity.
Complementation of P. fluorescens NCIMB 10586
mmpC AT DeletionMutant by BryP AT1 and BryP AT1AT2
To test the hypothesis that the two bryP-encoded AT domains
retain and display related functions, we assessed mutant
complementation in the mupirocin biosynthetic system from
P. fluorescens (e.g., production of pseudomonic acid (PA) A
[PA-A] [Figure 1B]). Of the two AT domains that comprise
MmpC, MmpC AT2 is most similar to BryP AT1 phylogenetically
(44.4% versus 24.1% to BryP AT2 amino acid identity), while
MmpC AT1 has a higher similarity to BryP AT2 (Figure 2; 28.2%
versus 23.5% to BryP AT1 amino acid identity). Bioinformatic
analysis has also revealed that MmpC likely contains a third
C-terminal domain of unknown function. In-frame deletion of
mmpC-encoded AT1 results in the reduction of pseudomonic86, November 24, 2008 ª2008 Elsevier Ltd All rights reserved 1177
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Trans-Acylation in Bryostatin Biosynthesisacid A (PA-A) to 13.5% of wild-type (WT) P. fluorescens, while no
PA-A is detected in the mmpC AT2 deletion mutant (Figure 3A).
The disk-diffusion bioassays showed that antibiotic activity re-
maining in the MmpC DAT1 mutant was significant (Figure 3B).
Complementation of the DmmpC AT1 mutant by BryP AT1 re-
sulted in restoration of PA-A to approximately 83% of WT levels
in the HPLC assays (Figure 3A). Similarly, in the disk-diffusion
bioassays, complementation by bryP AT1 restored bioactivity to
approximately 70% of WT levels (controls were roughly 30% of
WT levels), and the addition of two different concentrations of
isopropyl b-D-1-thiogalactopyranoside (IPTG) (0.1 and 0.5 mM)
did not affect the bioactivity of the extract (Figure 3B). In contrast,
expression of BryP AT1AT2 in the DMmpC AT1 mutant resulted in
much lower production of PA-A. The addition of IPTG resulted in
decreased levels of secondary metabolite production, suggest-
ing that higher levels of BryP AT1AT2 can inhibit biosynthesis,
possibly due to the formation of a nonfunctional protein-protein
complex. However, similar results occurred when plasmid-borne
mmpC AT2 was used to complement this mutant (El-Sayed et al.,
2003), suggesting that intracellular levels of trans-AT may be
Figure 2. Phylogeny of Discrete PKS ATs in
Relation to FAS and Embedded PKS ATs
Minimum evolution tree of amino acid sequences
of AT domains from B. neritina-‘‘Ca. Endobugula
sertula’’ and related PKS and FAS gene clusters.
Bootstrap analysis was performed 10,000 times,
and nodes with percentages greater than 50%
are labeled. Scale bar = 0.1 amino acid substitu-
tions per site. GenBank accession numbers are
listed after each sequence, and the sequences
utilized in this study are in bold.
important during biosynthesis. Interest-
ingly, neither BryP AT1 nor BryP AT1AT2
was able to complement the DmmpC
AT2 mutant, an in-frame deletion remov-
ing only AT2 (leaving both AT1 and the
third [unknown] domain of MmpC intact).
This result was surprising, since BryP
AT1 and MmpC AT2 cluster together in
the FAS-like PKS trans-AT group. Since
such AT domains clearly can retain the
ability to cross-complement (but that
this does not correlate with the specific
phylotype), it appears that there may be
no fundamental difference between the
activity of the two AT domains except in
the ad hoc way that they may have
adapted to their genetic and biochemical
context.
In Vitro Substrate Preference
of BryP
Sequence analysis of the discrete AT
domains suggests that BryP AT1 should
utilize malonyl-CoA as a substrate, as it
has several amino acids that are thought
to be involved in specificity for this pre-
cursor substrate (Met126 and Phe200 Streptomyces coelicolor
FabD numbering [Keatinge-Clay et al., 2003; Figure S1]). BryP
AT2 also has Phe200 (similar to ATs that mediate malonyl-CoA
transfer), but has Leu126 and Ile56 that are typically found in
AT domains selective for methylmalonyl-CoA (Keatinge-Clay
et al., 2003), suggesting that it may use an alternative substrate.
We therefore decided to investigate the substrate specificity of
the two AT domains comprising BryP, as well as to determine
the ability of the AT domains to transacylate carrier proteins
and complete PKS modules. AT-mediated transfer is a two-
step reaction (Keatinge-Clay et al., 2003). In the first step, the
extender unit substrate (usually either malonyl-CoA or methyl-
malonyl-CoA) is covalently attached to the active site serine of
the AT (termed ‘‘loaded’’) and CoASH is released; in the second
step, the extender unit undergoes transesterification from the
AT active site serine to the phosphopantetheine prosthetic
group of the ACP. In order to investigate the activity of BryP
with PKS ACPs and modules, a series of gene constructs were
cloned into Escherichia coli overexpression vectors, and the
purified polypeptides (BryP, as mono- and didomain fusion1178 Chemistry & Biology 15, 1175–1186, November 24, 2008 ª2008 Elsevier Ltd All rights reserved
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Trans-Acylation in Bryostatin Biosynthesisproteins) employed for in vitro assays (see Supplemental Data for
details).
The acyl-CoA substrate loading preference of the BryP variants
and their ability to transfer the substrates to an ACP from the
bryostatin gene cluster (BryB M7 ACP) was assessed. BryP AT1
was able to transfer [14C]-malonyl-CoA onto holo BryB M7
ACP, but not onto the apo protein (Figure S2). In addition, no
radioactivity was detected from the holo BryB M7 ACP that was
incubated in the presence of [14C]-malonyl-CoA or [14C]-methyl-
malonyl-CoA but lacking BryP AT1, demonstrating that BryB M7
ACP is not able to self-acylate with either substrate. Substrate
competition experiments were performed by incubating BryP
AT1 alone or with BryB M7 ACP with a mixture of [
14C]-labeled
and unlabeled malonyl-CoA and methylmalonyl-CoA. The rela-
Figure 3. Complementation of P. fluorescens MmpC Mutants by
BryP AT1 and BryP AT1AT2
(A) HPLC detection of PA-A production. Data are the mean of two experiments
where PA-A in supernatants of WT and mutant bacterial cultures were com-
pared, taking WT as 100% and expressing mutant levels relative to this. Error
bars indicate differences between duplicate runs. Variations in absolute values
between experiments were, on average, about 15%.
(B) Disk diffusion assays of P. fluorescens antibiotic activity comparing mutant
extracts against B. subtilis expressed as a percentage of WT activity, which
was taken as 100%, as in (A). Error bars represent standard deviations.Chemistry & Biology 15, 1175–11tive amount of labeling of each protein after SDS-PAGE autoradi-
ography suggests that BryP AT1 prefers to load and transfer to
BryB M7 ACP malonyl-CoA over methylmalonyl-CoA (Figure 4A).
The other BryP constructs (BryP AT1AT2 and three BryP AT2 con-
structs [32, 37, and 47; see Supplemental Data]) were also able to
transfer [14C]-malonyl- and [14C]-methylmalonyl-CoA to BryB M7
ACP, although it is evident that more malonyl-CoA is transferred
than methylmalonyl-CoA in the same amount of time (20 min)
(Figure 4B). In a time course experiment, there was no apparent
difference in the amount of labeling of both BryP AT1 and BryB
M7 ACP, suggesting that malonate is not released (e.g., hydro-
lyzed) from the ACP phosphopantetheine arm after 60 min
(data not shown). There was no significant difference in the activ-
ity of BryP AT1 in the range of pH tested (data not shown). In
addition, there was no difference detected in the activity of
BryP AT1 at pH 7.4 with and without EDTA and dithioerythritol
(DTE). The kinetic parameters of BryP AT1 transferring varying
concentrations of malonyl-CoA to BryB M7 ACP were deter-
mined. The KM was calculated to be 7 mM (±0.6 SE) and kcat/KM
was 0.1 mM1 s1 (Figure 4C). Because of the decreased solubil-
ity of BryB M7 ACP at high concentrations, kinetic experiments
that varied its concentration were not performed. The KM value
of BryP AT1 with malonyl-CoA as the substrate (7 mM) is a little
more than five times lower than the value reported for FenF
with MycA ACP2, but the kcat value is 24 times less than FenF
(Aron et al., 2007). Both the KM and kcat values are much lower
than those calculated for the S. coelicolor and E. coli FAS MAT
and ACP (Szafranska et al., 2002), suggesting that, although
BryP AT1 has a low turnover rate, it has a high affinity for
malonyl-CoA.
Fourier transform ion cyclotron mass spectrometry (FT-ICR
MS) was employed to qualitatively confirm the types of sub-
strates loaded froma poolof acyl-CoAs and to verify the predicted
active-site serine of BryP AT1. Briefly, BryP AT1 was incubated
with an equimolar mixture of malonyl-, methylmalonyl-, acetyl-,
and propionyl-CoA, and analyzed intact by FT-ICR MS. Three
peaks were detected in the repeating isotope pattern of the
loaded BryP AT1 (Figure 4D, top panels). For clarity, the mass
shift in the +37 charge state is used in the following discussion,
although similar shifts in mass were apparent for all charge
states observed. Unloaded BryP AT1 at the expected mass was
observed in the sample, as well as BryP AT1 with a shift in m/z
of 2.25 or 83.2 Da, likely due to the addition of malonyl-CoA.
Additionally, a shift in m/z of 2.73 in the +37 charge state was
observed, correlating to the addition of 101 Da, and the loading
of methylmalonyl-CoA. The control reaction resulted in only
unloaded BryP AT1 (Figure 4D, bottom panels). In a subsequent
experiment, BryP AT1 was subjected to proteolytic digestion prior
to FT-ICR MS analysis to ensure that loading occurs on the
predicted active site serine residue. A Glu-C-derived peptide,
SHKPSYVAGHSLGE, was identified by MS/MS in the malonyl-
and methylmalonyl-loaded forms. A partial tryptic peptide, TQFT
QPALYIINALSFLDKIELESHKPSYVAGHSLGEYNALFAAGAFDF
LTGLK, was also identified by MS/MS in the malonyl- and meth-
ylmalonyl-loaded forms. The predicted active site serine (bold)
was determined to be the modified residue in both cases.
LC/MS was used to investigate acyl group transfer from BryP
AT1 to another Bry ACP, BryA M3 ACP (Figure 1A). Both proteins
were incubated together in the presence or absence (control) of86, November 24, 2008 ª2008 Elsevier Ltd All rights reserved 1179
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Constructs
(A) Autoradiography of SDS-PAGE of BryP AT1
substrate preference experiment. Lanes 1 and 2,
malonyl-CoA/[14C]-malonyl-CoA; lanes 3 and 4,
methylmalonyl-CoA/[14C]-malonyl-CoA; lanes 5
and 6, methylmalonyl-CoA/[14C]-methylmalonyl-
CoA; and lanes 7 and 8, malonyl-CoA/[14C]-meth-
ylmalonyl-CoA. Lanes 1, 3, 5, and 7 contain BryP
AT1 only, and lanes 2, 4, 6, and 8 contain BryP
AT1 and BryB M7 ACP.
(B) Autoradiography of SDS-PAGE of BryP con-
structs loading onto BryB M7 ACP. Lanes 1 and
6, BryP AT1 + BryB M7 ACP; lanes 2 and 7, BryP
AT1AT2 + BryB M7 ACP; lanes 3 and 8, BryP
AT2(32) + BryB M7 ACP; lanes 4 and 7,
BryP AT2(37) + BryB M7 ACP; lanes 5 and 10,
BryP AT2(47) + BryB M7 ACP; and lane L, ladder.
Lanes 1–5, [14C]-malonyl-CoA; lanes 6-10,
[14C]-methylmalonyl-CoA.
(C) Kinetics of BryP AT1 loading [
14C]-malonyl-
CoA onto BryB M7 ACP. Reactions and no-
enzyme controls were run in triplicate.
(D) FT-ICR MS analysis (+37 charge state) of full
BryP AT1 incubated with a mixture of acyl-CoAs
(top panels) or no substrate (bottom panels).
Asterisk indicates peak that is magnified (right
panels).equimolar amounts of acetyl-, malonyl-, methylmalonyl-, and
propionyl-CoA. Experiments in the absence of BryP AT1 showed
that the holo ACP did not self-load to an appreciable degree
(data not shown). In the presence of BryP AT1 and the acyl-
CoAs, BryA M3 ACP peaks increased in mass by 5.1 m/z in the
+17 charge state, an 86.7 Da mass increase consistent with
a preference for malonyl-CoA (Figure 5). An additional peak
with a mass shift of 179 Da is observed in the LC-MS data; this
is likely a-N-6-phosphogluconoylation, a common posttransla-
tional modification observed on fusion proteins with a 63 His
affinity tag (Geoghegan et al., 1999). This additional peak
exhibits the same mass shift and preference as the holo ACP.
Taken together, these data suggest that BryP AT1 can load
both malonyl- and methylmalonyl-CoA (Figure 4), but that malo-
nate is preferentially transferred to the Bry ACPs. The preference
for malonyl-CoA over methylmalonyl-CoA has been demon-
strated for other trans-AT gene clusters. In vitro assays with the
myxovirescin gene cluster from Myxococcus xanthus DK1622
trans-AT didomain (TaV) (Simunovic et al., 2006) have shown
that TaV AT2 (which is a FAS-like trans-AT [Figure 2]) prefers
malonyl-CoA over methylmalonyl-CoA, acetyl-CoA, and pro-
pionyl-CoA (Calderone et al., 2007). In addition, TaV AT2 was able
to acylate both discrete and embedded ACP domains from the
gene cluster (Calderone et al., 2007). No in vitro assays were per-
formed on TaV AT1 (Calderone et al., 2007), which is more similar
to BryP AT2 (Figure 2). The trans-AT associated with the bacil-
laene cluster in B. subtilis (PksC) (Butcher et al., 2007), which
forms a clade with BryP AT1 (Figure 2), was also shown to prefer-1180 Chemistry & Biology 15, 1175–1186, November 24, 2008 ª200entially load malonyl-CoA over acetyl-CoA and methylmalonyl-
CoA, and transfer malonyl-CoA onto a cognate, discrete ACP
(AcpK) (Calderone et al., 2006).
BryP Exhibits Flexibility for Transferring
Malonate onto ACPs
The mono- and didomain constructs of BryP were assayed for
their ability to transfer substrates onto an ACP from another
PKS (pikromycin PikAIII M5 ACP [Xue et al., 1998]), and a peptidyl
carrier protein (PCP) from an aminocoumarin (clorobiocin) bio-
synthetic gene cluster (Pojer et al., 2002). BryP AT1 transferred
[14C]-malonyl-CoA onto a variety of carrier proteins, including
the BryB M7, PikAIII M5 ACPs, as well as the holo (but not the
apo) forms of CloN5 (Figure S2). The BryP didomain (BryP
AT1AT2) and the didomain single mutants BryP AT1
AT2 and
BryP AT1AT2
 were able to catalyze loading of each of the carrier
proteins presented. The double mutant BryP AT1
AT2, as
expected, did not catalyze acyl transfer to any of the carrier
proteins. One BryP AT2 construct (37) was also able to catalyze
transfer of malonyl-CoA to each of the carrier proteins (data not
shown). The flexibility of BryP in transferring malonate to ACPs
from two PKS gene clusters (bryostatin and pikromycin) was
similar to that of FenF, a discrete FAS-like AT in the mycosubtilin
gene cluster (Duitman et al., 1999). FenF did not exhibit signifi-
cant preference in vitro for the substrate (malonyl-CoA) ACP
compared to the loading (palmitoyl-CoA) ACP in MycA (Aron
et al., 2007). Conversely, while BryP was also able to transfer
malonate onto a PCP from the clorobiocin biosynthetic gene8 Elsevier Ltd All rights reserved
Chemistry & Biology
Trans-Acylation in Bryostatin BiosynthesisFigure 5. LC/MS Analysis of BryP AT1 Transfer of acyl-CoAs to holo BryA M3 ACP
Reactions with (A–C) and without (D–F) acyl-CoAs are shown.
(A and D) Reversed-phase HPLC TIC chromatogram.
(B and E) Zoom of full spectrum.
(C and F) Zoom on single charge state with assignments. mal, malonyl; aNG, a-N-6-phosphogluconoylation.(Figure S3), FenF was eight times less efficient loading malonyl-
CoA onto one of the PCP domains in MycA (Aron et al., 2007).
Moreover, the discrete AT (LnmG) in the leinamycin gene cluster
was not able to load malonyl-CoA onto an excised PCP from that
PKS/NRPS gene cluster (Cheng et al., 2003), suggesting that
either the PCP domain is unable to bind to malonyl-CoA, or
that the discrete ATs are unable to recognize or interact with
the PCP. As both the hybrid PKS/NRPS leinamycin and myco-
subtilin gene clusters contain ACP and PCP domains, it would
be advantageous for the discrete ATs to discriminate between
the two types of carrier proteins to avoid biosynthetic derailment
by acylating the incorrect thiolation domain. However, because
the bryostatin gene cluster is only composed of PKS modules,
BryP may not have evolved to selectively interact with ACP
versus PCP domains.
BryP-Catalyzed Acyl Transfer onto PKS Modules
from the Pikromycin, Erythromycin,
and Bryostatin Gene Clusters
A previous study demonstrated the ability of the S. coelicolor
FAS MAT to catalyze transfer of malonyl-CoA onto the ACP of
an EryAIII module 6 AT mutant (Kumar et al., 2003). We decided
to extend this type of trans-AT substrate delivery analysis using
BryP toward a series of PKS modules, including PikAIV M6 (Pik
module 6), EryAIII M6, and BryB M4. BryP AT1 was not able to
load malonyl- or methylmalonyl-CoA onto the PikAIV M6 AT
module (Figure 6A), the native substrate of which is methylma-Chemistry & Biology 15, 1175–118lonyl-CoA (Xue et al., 1998). The WT PikAIV M6 was able to
self-load and transfer methylmalonyl-CoA, but not malonyl-
CoA. Similarly, WT EryAIII M6 was able to self-load methylma-
lonyl-CoA (its native substrate [Donadio et al., 1991]) (data not
shown), but not malonyl-CoA (Figure 6B). In contrast to the
PikAIV M6 AT, BryP AT1 was able to effectively transfer
malonyl-CoA onto EryAIII M6 AT (Figure 6). Most significantly,
BryP AT1 was able to transfer [
14C]-malonyl-CoA onto the holo
form of the native module BryB M4, but was unable to do so
onto the apo preparation of BryB M4 (Figure 6B). The BryP AT di-
domain was able to transfer malonyl-CoA onto both EryAIII M6
AT and the native module BryB M4 (Figures 7A and 7B). Both
single-mutant BryP AT didomain proteins were able to load
malonyl-CoA onto these individual modules, although, based
on relative signal strengths of the BryP AT1AT2 point mutants,
it appears that AT1 is more active than AT2 (Figure 7B, lanes 4,
5, 11, and 12). The BryP AT double mutant was not able to trans-
fer malonyl-CoA onto the module. Neither BryP AT1 nor the dido-
main was able to transfer methylmalonyl-CoA onto either EryAIII
M6 AT or the native BryB M4 module (Figure 7C). Interestingly,
BryP AT2(37) was able to transfer methylmalonyl-CoA onto the
EryAIII M6 AT module, but was unreactive toward BryB M4
(Figure 7C, lane 7). In vivo, these trans-ATs are hypothesized
to acylate ACP domains that are part of a multidomain module.
While the mono- and didomain constructs of BryP were able
to transfer malonyl-CoA onto modules BryB M4 and EryAIII
M6 AT (Figures 6B and 7B), BryP AT1 was unable to transfer6, November 24, 2008 ª2008 Elsevier Ltd All rights reserved 1181
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that there may be some specificity regarding the interaction
between the trans-AT and the module.
All of the bryostatins characterized to date have two gem-
dimethyl groups (at C8 and C18; Figure 1). The modules that
are putatively responsible for the assembly of those regions
contain MT domains (M4 and M9) (Sudek et al., 2007) that could
add either one or two methyl groups to the a-carbon. We were
motivated to investigate the substrate preference of the two AT
domains of BryP, as they could possibly load different substrates
(malonyl-CoA or methylmalonyl-CoA) onto the ACPs from these
modules that could then be methylated either once or twice
by the embedded MT enzymatic domains, resulting in the gem-
inal dimethylated carbon atoms. Two other natural products
that have gem-C-dimethyl groups are the mixed PKS/NRPS
compounds epothilone (Molnar et al., 2000) and yersiniabactin
(Gehring et al., 1998), and both have embedded MT domains
within the PKS module, which is responsible for the elongation
and modification of the corresponding portion of the molecule.
The biosynthetic origins for the methyl groups have been inves-
tigated, and, interestingly, two different mechanisms have been
described. In yersiniabactin biosynthesis, data from in vivo feed-
ing studies (Gehring et al., 1998) and in vitro assays with purified
enzymes (Miller et al., 2002) suggest that the polyketide chain is
elongated by malonyl-CoA, and both methyl groups originate
from S-adenosyl-methionine. However, in epothilone biosynthe-
sis, several lines of evidence, including feeding studies (Gerth
et al., 2000) and bioinformatic analysis of the AT domain sub-
strate preference (Molnar et al., 2000; Petkovic et al., 2008),
Figure 6. Autoradiography of SDS-PAGE of PKS Module Loading by
BryP AT1
(A) Loading of PikAIV M6 WT and AT. Lanes 1 and 2, PikAIV M6 WT + BryP
AT1; lane 3, PikAIV M6 AT
 + BryP AT1; and lane L, ladder. Substrate for middle
panel is [14C]-malonyl-CoA, and substrate for lower panel is [14C]-methylma-
lonyl-CoA.
(B) Loading of EryAIII M6 WT and AT, and BryB M4 with [14C]-malonyl-CoA by
BryP AT1. Lane 1, EryAIII M6 WT + no BryP AT1; lane 2, EryAIII M6 AT
 + no
BryP AT1; lane 3, EryAIII M6 AT
 + BryP AT1; lane L, ladder; lane 4, apo
BryB M4 + BryP AT1; and lane 5, BryB M4 + BryP AT1.1182 Chemistry & Biology 15, 1175–1186, November 24, 2008 ª200support the hypothesis that methylmalonyl-CoA is incorporated
into the polyketide chain by the embedded AT, followed by
C-methylation on the a-carbon. One of the Bry MT-containing
modules was targeted (BryB M4) (Sudek et al., 2007) in efforts
to determine the likely mode of methylation. When methylma-
lonyl-CoA was tested as a substrate, the single BryP AT2 domain
was able to label only EryAIII M6 AT, the natural substrate of
which is methylmalonyl-CoA (Donadio et al., 1991). As neither
the BryP didomain nor the BryP AT1
AT2 mutant was able to
acylate EryAIII M6 AT with methylmalonyl-CoA, having the addi-
tional domain (AT1) may interfere with the ability of AT2 to load the
module with methylmalonyl-CoA. However, since BryP was not
able to load methylmalonyl-CoA onto BryB M4, it seems more
likely that the MT adds two methyl groups as in yersiniabactin
biosynthesis. The dimethylation at the C-8 and C-18 positions
on the growing bryostatin chain elongation intermediate is
consistent with the general malonyl-CoA selectivity of all known
trans-AT domains investigated from various Gram-positive,
Gram-negative, and microbial symbiont natural product path-
ways (Nguyen et al., 2008). This is also consistent with the lack
of a methylmalonyl-CoA precursor pool in all known g-proteo-
bacteria that includes the uncultured bacterial symbiont
‘‘Candidatus Endobugula sertula,’’ which is responsible for the
biosynthesis of the bryostatin anticancer natural products.
SIGNIFICANCE
In this study, we demonstrate that BryP exhibits flexibility
when loading malonyl- or methylmalonyl-CoA, but prefers
to transfer malonate to excised and modular acyl carrier
proteins (ACPs). Furthermore, BryP is able to transfer the
predicted extender unit, malonyl-CoA, onto a complete
native module from the presumed bryostatin biosynthetic
gene cluster. Results from this investigation suggest that
the geminal dimethyl groups at C-8 and C-18 on the bryolac-
tone ring system are derived from double C-methylation of
a malonate extender unit during chain elongation. While
several large polyketide synthase (PKS) gene clusters from
uncultivated symbiotic microbes have been cloned and se-
quenced (Partida-Martinez and Hertweck, 2007; Piel, 2002;
Piel et al., 2004), this is, to our knowledge, the first instance
that a large portion of a PKS gene cluster from an unculti-
vated symbiotic microbe has been overexpressed and
demonstrated to function with cognate enzymatic domains.
In vivo assays with Pseudomonas fluorescens mupirocin
DAT mutants showed that BryP is only able to complement
one of the AT domain mutant strains. A number of questions
remain to be explored about how these domains physically
interact with PKS modules and full PKS polypeptides and
megacomplexes. Finally, this is the first step toward demon-
strating unequivocally that the assigned Bry metabolic sys-
tem produces the bryostatins.
EXPERIMENTAL PROCEDURES
Sequence and Phylogenetic Analysis of the AT Domains
Shallow and deep bryP sequences (Sudek et al., 2007) were analyzed by
BLAST (Altschul et al., 1990). The amino acid sequences were aligned with
the sequences of other trans-AT domains as well as integrated AT domains8 Elsevier Ltd All rights reserved
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evolution phylogenetic tree was generated using MEGA version 4 (Tamura
et al., 2007). Subjecting the alignment to alternative algorithms (neighbor
joining and maximum parsimony) resulted in similar topology.
Generation ofmmpC AT In-FrameDeletionMutants in theMupirocin
Producer, P. fluorescens NCIMB10856
Construction of an in-frame deletion in MmpC AT2 has been previously
described (El-Sayed et al., 2003). Deletion of MmpC AT1 was carried out
with suicide plasmid pJHAT101 that contains an mmpC deletion of 907 bp
(23,214–24,120 bp inclusive, database numbering). This creates a frame shift
in the remaining MmpC AT1 sequence such that a 24 codon ORF will deliver
ribosomes to the ribosome binding site and ATG start codon at the beginning
of the AT2 domain of mmpC. Production of pseudomonic acids by this mutant
was verified, suggesting that MmpC AT2 was still functional.
Construction of P. fluorescens expression plasmids.
For in trans expression of bryostatin ATs in P. fluorescens AT deletion strains,
domains were cloned into the IncQ vector pJH10 under the control of the tac
promoter (El-Sayed et al., 2003). BryP AT1 was restricted from pNL020 (Table
S1) and ligated into pJH10 to give pJS261. The AT didomain (BryP AT1AT2)
was PCR amplified from a fosmid subclone (MM5_2_BO7) using primers
BryP_AT1_F and BryP_AT2_R (Table S2), and cloned into pJH10 to give
pJS262. Inserts were verified by sequencing. Complementation plasmids
were introduced into the MmpC mutant strains of P. fluorescens by conjuga-
tion with plasmid-bearing E. coli S17-1, as described previously (Hothersall
et al., 2007). Positive colonies were screened for metabolite production. Anti-
biotic disk-diffusion bioassays using B. subtilis cultures were used to screen
for mupirocin, which is a mixture of PA, dominated by PA-A (90%). Direct
Figure 7. Loading of Substrates onto PKS
Modules by BryP
(A–C) (A) Coomassie brilliant blue stained gels, and
autoradiography with (B) [14C]-malonyl-CoA and
(C) [14C]-methylmalonyl-CoA substrates. Lane L,
ladder; lanes 1–7, EryAIII M6 AT; lanes 8–14,
BryB M4. Lanes 1 and 8, no BryP; lanes 2 and 9,
BryP AT1; lanes 3 and 10, BryP AT1AT2; lanes 4
and 11, BryP AT1
AT2; lanes 5 and 12, BryP
AT1AT2
; lanes 6 and 13, BryP AT1AT2, and lanes
7 and 14, BryP AT2(37).
quantification of PA-A was performed by HPLC
analysis of strain extracts. Both experiments were
run in duplicate.
In Vitro Substrate Preference of BryP
Radioactive assays of BryP activity
To determine the ability of BryP to acylate various
carrier proteins and PKS modules, each was indi-
vidually incubated with the BryP proteins and
radiolabeled substrate (see cloning and overex-
pression details in Supplemental Data). In general,
the reactions were run in 50 mM HEPES buffer,
pH 7.4, 5–10 mM carrier protein or module protein,
1–8 mM BryP protein, and 0.4–0.5 mM substrate.
The enzymes were equilibrated at room tempera-
ture (RT) for 5 min before the substrate was added.
Reactions proceeded for 5–20 min at RT, and were
quenched by the addition of 23 SDS-PAGE
loading buffer with no reducing agent. The samples
were mixed and loaded onto SDS-PAGE gels.
After electrophoresis, the gels were stained with
either Coomassie blue or SimplyBlue (Invitrogen)
stains, and destained. The gels were dried (Bio-
Rad), and placed into a phosphoimager cassette
(Amersham Biosciences). After 5 days, the phosphoimager screen was
scanned, and the images were analyzed.
To determine the substrate preference of BryP AT1, radiolabeled and unla-
beled malonyl- and methylmalonyl-CoA were mixed in separate reactions.
[14C]-malonyl- and [14C]-methylmalonyl-CoA (55 mCi/mmol; ARC, Inc.) were
mixed with unlabeled malonyl- and methylmalonyl-CoA to result in 0.5 mM
total concentration of the substrates. After a 5 min incubation at RT, the
amount of labeling on BryP AT1 (2 mM) and BryB M7 ACP (10 mM) was visual-
ized by SDS-PAGE autoradiography. The BryP AT didomain (BryP AT1AT2) and
three BryP AT2 constructs (AT2[32], AT2[37], AT2[47]) were assayed for the abil-
ity to transfer [14C]-malonyl-CoA and [14C]-methylmalonyl-CoA (0.5 mM) to
BryB M7 ACP (20 mM). As the BryP didomain and BryP AT2 constructs could
not be purified to homogeneity, their concentration could not be determined
accurately. A 6 ml aliquot of the eluted protein from the nickel-nitrilotriacetic
acid column was used in each reaction; BryP AT1 was added to a final concen-
tration of 4 mM. The reaction was quenched after 20 min. In a time-course
experiment, 7.5 mM of BryB M7 ACP was incubated with 1 mM BryP AT1 and
0.4 mM [14C]-malonyl-CoA, and the reactions were quenched after 5, 10, 15,
30, and 60 min.
A protein precipitation assay was used to quantify the activity of BryP AT1 in
the presence of BryB M7 ACP. The activity of BryP AT1 was determined in
HEPES buffer (50 mM) with different pH values ranging from 6.0 to 9.2. These
assays were conducted by incubating BryP AT1 (1 nM) with [
14C]-malonyl-CoA
(0.1 mM) and BryB M7 ACP (50 mM), and measuring the amount of radiolabel
bound to BryB M7 ACP after acid precipitation and scintillation counting based
on the method previously described (Koppisch and Khosla, 2003). EDTA and
DTE (2 mM each) was added to each reaction; one duplicate set of reactions at
pH 7.4 was run without EDTA or DTE to determine if they affected BryP AT1
activity. The reactions and no-enzyme controls (bovine serum albumin [BSA]Chemistry & Biology 15, 1175–1186, November 24, 2008 ª2008 Elsevier Ltd All rights reserved 1183
Chemistry & Biology
Trans-Acylation in Bryostatin Biosynthesis10 mg/ml) were run in duplicate. The reaction mixture was equilibrated at RT
for 5 min before the enzyme (or BSA) was added, and the reaction proceeded
at RT for 5 min. The amount of radiolabel incorporation versus background
was compared among the duplicate reactions at the different pHs, and
between the pH 7.4 samples run with and without DTE and EDTA.
The reaction kinetics of BryP AT1 with malonyl-CoA and purified BryB M7
ACP were determined using the TCA precipitation method at pH 7.4. The final
concentration of BryP AT1 was 1 nM, and the final concentration of BryB M7
ACP was 50 mM. The concentration of [14C]-malonyl-CoA varied from 0.2 to
250 mM. The loading reaction proceeded for 5 min on ice, after which the
reaction was quenched. The reaction and controls (1 nM BSA) were performed
in triplicate. Kinetic parameters were not obtained for varying concentrations
of BryB M7 ACP, as this protein would precipitate out of solution at high
concentrations.
FT-ICR MS analysis of BryP AT1
BryP AT1 (5 mM) was reacted with a pool of 250 mM acetyl-, malonyl-, methyl-
malonyl-, and propionyl-CoA in 50 mM HEPES (pH 7) buffer and 1 mM TCEP.
After incubation for 30 min, samples were acidified with 1% formic acid. Intact
protein samples were desalted with Handee Microspin columns (Pierce)
packed with 20 ml of 300 A˚ polymeric C4 resin (Vydac). Samples were loaded
onto the columns and washed with 30 column volumes of 0.1% formic acid
prior to elution with 10 column volumes of 50% acetonitrile plus 0.1% formic
acid. Intact protein samples were analyzed by an FT-ICR MS (APEX-Q with
Apollo II ion source and actively shielded 7T magnet; Bruker Daltonics). Data
was gathered from m/z 250–2000 utilizing direct infusion electrospray ioniza-
tion in positive ion mode. Electrospray was conducted at 3600 V with 24–60
scans per spectra utilizing 0.5 s external ion accumulation in the hexapole prior
to analysis in the FT-ICR using a loop value of 15. All CID MS/MS was per-
formed external to the FT-ICR cell with quadrapole mass selection. In order
to confirm that the modification occurred on the active site serine, BryP AT1
was then subjected to proteolytic digestion after reaction with the acyl CoA
pool and FT-ICR MS analysis. Glu-C (Worthington Biochemical) or trypsin
(Promega) (1/100 [w/w]) was added to the samples, and digestion proceeded
for 4 hr at 37C. Proteolytic peptides were desalted as above with the excep-
tion that C18 resin was utilized. FT-ICR MS analysis was performed as above,
except that the loop value was 4 and the ion accumulation time was 1 s.
LC-MS analysis of BryA M3 ACP
BryP AT1 (2 mM) and BryP AT1 (20 mM) were reacted with a pool of 250 mM ace-
tyl-, malonyl-, methylmalonyl-, and propionyl-CoA. Reactions were incubated
for 45 min in 50 mM HEPES (pH 7) and 1 mM TCEP, and were quenched by
diluting 23 in 6 M urea, 100 mM HEPES (pH 6). A 10 ml sample of this mixture
was analyzed by LC-MS with a Shimadzu LCMS-2010EV (Columbia, MD) after
separation on a PLRP-S 23 50 mm, 4000 A˚, 8 mm polymeric RP-HPLC column
(Varian, Palo Alto, CA) heated to 50C. Samples were desalted online for 5 min
with 95% buffer A (98.9% water, 1% acetonitrile, 0.1% formic acid) and 5%
buffer B (1% water, 98.9% acetonitrile, and 0.1% formic acid), followed by gra-
dient elution over 20 min. Profile mode data was gathered from m/z 400–2000
utilizing electrospray ionization in positive ion mode.
BryP Transfer to Other ACPs
The ability of BryP AT1 to acylate a variety of carrier proteins was assayed
by in vitro incubation of the proteins with radiolabeled substrates followed
by SDS-PAGE autoradiography, as described previously. Purified BryP AT1
(2 mM) was incubated with both apo and holo BryB M7 ACP (10 mM), 0.4 mM
[14C]-malonyl-CoA, and [14C]-methylmalonyl CoA for 5 min at RT. The ability
of the other BryP constructs (BryP AT1AT2, BryP AT2[37], and site mutants
BryP AT1
AT2, AT1AT2, AT1AT2) to load [
14C]-malonyl-CoA onto a variety
of carrier proteins was assessed in a similar fashion. The carrier proteins
used were BryA M3 ACP (apo and holo), PikAIII M5 ACP, and CloN5 (apo
and holo). Each purified carrier protein preparation (20 mM) was incubated
with the BryP protein and [14C]-malonyl-CoA (0.2 mM) for 10 min at RT. The
BryP concentrations added were 4 mM BryP AT1, 0.9 mg/ml BryP didomains,
and 0.6 mg/ml of BryP AT2(37). The reaction proceeded for 10 min at RT.
BryP Loading onto Modules from the Pikromycin,
Erythromycin, and Bryostatin Gene Clusters
WT PikAIV M6 and the AT mutant (PikAIV M6 AT) were incubated with BryP
AT1 and [
14C]-malonyl-CoA or [14C]-methylmalonyl-CoA. WT PikAIV was1184 Chemistry & Biology 15, 1175–1186, November 24, 2008 ª200tested at 5 and 10 mM, and PikAIV AT was tested at 10 mM. BryP AT1
(2 mM) was added, and after equilibration, either radiolabeled substrate was
added (0.4 mM). After 5 min at RT, the reaction was quenched. Next, BryP
AT1 was assayed with malonyl-CoA and EryAIII M6 AT
 or BryB M4. BryP
AT1 (4 mM) and [
14C]-malonyl-CoA (0.5 mM) were incubated with EryAIII M6
AT (10 mM) for 10 min at RT. The amylose resin elutions of BryB M4 were
used without further purification; the pooled fractions were assayed at a final
concentration of 2.2 mg/ml total (holo BryB M4) or 1.1 mg/ml (apo BryB M4).
The other BryP constructs were tested for their ability to load both malonyl-
and methylmalonyl-CoA onto the EryAIII M6 AT and BryB M4 modules. The
final concentration of EryAIII M6 AT was 5 mM, that of BryP AT1 was 4 mM,
and that of substrate was 0.5 mM. The final concentration of the BryB M4 prep-
aration was 3.3 mg/ml, that of the BryP AT didomain preparations was 0.9 mg/
ml, and that of BryP AT2(37) was 0.6 mg/ml. The reactions were quenched after
15 min at RT.
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Supplemental Data include Supplemental Experimental Procedures, Supple-
mental Results, three figures, two tables, and Supplemental References
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